| Identification | Back Directory | [Name]
5-HexynaMide, 6-[2-[[4-aMino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)- | [CAS]
1293915-42-0 | [Synonyms]
RV-1729
RV-1729;RV 1729;RV1729
6-[2-[[4-Amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)met
6-[2-[[4-Amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-4-oxo-quinazolin-5-yl]-N,N-bis(2-methoxyethyl)hex-5-ynamide
6-(2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide
5-HexynaMide, 6-[2-[[4-aMino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)- | [Molecular Formula]
C39H39ClN8O5 | [MDL Number]
MFCD27987097 | [MOL File]
1293915-42-0.mol | [Molecular Weight]
735.23 |
| Hazard Information | Back Directory | [Uses]
RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ). RV-1729 identifies inhibition of the PI3K isotype by quantifying the release of phosphatidylinositol 3,4, 5-triphosphate (PIP3) (IC50=12 nM), showing twice the selectivity for PI3Kδ relative to PI3Kγ. RV-1729 is also 16 times more selective to PI3Kα. RV-1729 regulates immune and inflammatory responses by inhibiting PI3Kδ. RV-1729 can be used in studies of asthma and chronic obstructive pulmonary disease (COPD)[1]. | [References]
[1] Norman P. Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729[J]. Expert Opinion on Therapeutic Patents, 2014, 24(4): 471-475. DOI:10.1517/13543776.2014.865725 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Matrix Scientific
|
| Tel: |
803 788-9494 All other calls |
| Website: |
www.matrixscientific.com |
|